Our Offer
With approximately €1 billion in expected sales in 2022, EUROAPI will rank #1 in small molecules APIs, and our strong innovation and R&D capabilities allow us to accelerate our development in more complex molecule segments through CDMO activities.
At approximately 200 APIs, EUROAPI offers one of the largest portfolios in the industry, addressing a wide variety of patients and providing coverage for more than 80 countries.
We provide expertise in Quality, Regulatory and Supply and have dedicated commercial teams for our clients around the globe.